A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|2||Active, not recruiting||
A Study of DCC-2701 in Participants With Advanced Solid Tumors
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
† Study has passed its completion date and status has not been verified in more than two years.